Wedbush Equities Analysts Reduce Earnings Estimates for CMPX

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Investment analysts at Wedbush reduced their Q3 2025 earnings estimates for Compass Therapeutics in a note issued to investors on Monday, August 11th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.14) per share for the quarter, down from their prior forecast of ($0.13). The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.55) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.32) EPS.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01).

CMPX has been the topic of a number of other reports. Guggenheim upped their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. D. Boral Capital reiterated a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Tuesday. Finally, Raymond James Financial upgraded shares of Compass Therapeutics to an “outperform” rating and set a $9.00 target price on the stock in a research report on Tuesday, July 1st. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $12.89.

Compass Therapeutics Trading Down 4.8%

Shares of CMPX stock opened at $2.95 on Wednesday. Compass Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.08. The firm’s 50 day moving average is $2.79 and its 200-day moving average is $2.50. The firm has a market capitalization of $407.93 million, a price-to-earnings ratio of -6.56 and a beta of 1.49.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. raised its stake in shares of Compass Therapeutics by 11.3% during the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock worth $57,000 after buying an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Compass Therapeutics by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company’s stock worth $463,000 after buying an additional 5,590 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after buying an additional 9,451 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock valued at $69,000 after purchasing an additional 11,326 shares in the last quarter. Finally, Creative Planning bought a new stake in Compass Therapeutics in the second quarter valued at approximately $30,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.